1. Home
  2. PRT vs BTAI Comparison

PRT vs BTAI Comparison

Compare PRT & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PermRock Royalty Trust Trust Units

PRT

PermRock Royalty Trust Trust Units

N/A

Current Price

$2.09

Market Cap

27.0M

Sector

Energy

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$0.07

Market Cap

24.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRT
BTAI
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.0M
24.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PRT
BTAI
Price
$2.09
$0.07
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
25.1K
12.7M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
13.45%
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
N/A
$910.15
P/E Ratio
$7.78
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.82
$0.07
52 Week High
$4.01
$3.19

Technical Indicators

Market Signals
Indicator
PRT
BTAI
Relative Strength Index (RSI) 33.40 19.82
Support Level $2.02 N/A
Resistance Level $2.32 $1.22
Average True Range (ATR) 0.07 0.06
MACD -0.01 -0.07
Stochastic Oscillator 17.86 0.57

Price Performance

Historical Comparison
PRT
BTAI

About PRT PermRock Royalty Trust Trust Units

PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: